(12) **Translation of European patent specification**

(11) **NO/EP 3076972 B1**

(19) NO

NORWAY

(51) Int Cl.
A61K 31/496 (2006.01)
A61K 31/337 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.03.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.10.06
(86)	European Application Nr.	13895342.7
(86)	European Filing Date	2013.10.11
(87)	The European Application's Publication Date	2016.10.12
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	BeyondSpring, Inc., Sertus Chambers PO Box 2547 Cassia Court Camana Bay, Grand Cayman, Cayman-øyene
(72)	Inventor	HUANG, Lan, No. 9 East Liaohe Road Dalian Development Zone, Dalian Liaoning 116001, Kina
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **CANCER TREATMENT WITH COMBINATION OF PLINABULIN AND TAXANE**

(56) References Cited:

WO-A1-2005/077940
MILLWARD M. ET AL: "Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 3, 16 February 2011 (2011-02-16), pages 1065-1073, XP035052851,
SATO I. ET AL.: "Prediction of docetaxel monotherapy-induced neutropenia on the monocyte parentage.", ONCOLOGY LETTERS, vol. 3, 2012, pages 860-864,
AAVV: "Febrile Neutropenia", JAMA ONCOLOGY, vol. 3, no. 12, 2017, page 251,
CRAWFORD J. ET AL.: "Myeloid Growth Factors, version 2.2017", J. NATL. COMPR. CANC. NETW., vol. 15, no. 12, 2017, pages 1520-1541,
MICHAEL MILLWARD ET AL.: 'phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel' THE JOURNAL OF NEW ANTICANCER AGENTS vol. 3, no. 30, 16 February 2011, pages 1065 - 1073, XP035052851 DOI: 10.1007/S10637-011-9642-4
MILLWARD M. ET AL.: "Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel.", J. CLIN. ONCOL., vol. 27, no. 15S, May 2009 (2009-05), page 3571,
AAVV: "ICH Harmonised Tripartite Guideline: Nonclinical Exaluation for Anticancer Pharmaceuticals", 2009, International Conference on Harmonsation of Technical Requirements for Registration of Pharmaceuticals for Human Use vol. S9
A. C. MITA ET AL: "Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC).", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15_suppl, 20 May 2010 (2010-05-20), pages 7592-7592, XP055394409, US ISSN: 0732-183X, DOI: 10.1200/jco.2010.28.15_suppl.7592
AAVV: "Common Terminology Crteria for Adverse Events (CTCAE) v5.0", 27 November 2017 (2017-11-27), MedDRA

Patentkrav

1. Plinabulin til bruk for å redusere nøytropeniraten hos en nøytropeni av grad 3 eller 4 hos et individ som blir administrert med 75 mg/m^2 docetaksel, der plinabulinet blir administrert intravenøst med fra ca. 20 mg/m^2 til ca. 30 mg/m^2, der plinabulinet blir administrert innen 1 t og 24 t et atter docetakselet er blitt administrert.

2. Plinabulin til bruk ifølge krav 1, der dosen med plinabulin er ca. 20 mg/m^2 eller ca. 30 mg/m^2

3. Plinabulin til bruk ifølge krav 1 eller 2, der individet har ikke-småcellet lungekreft (NSCLC).